Literature DB >> 3734137

Pharmacokinetics: time-dependent changes--autoinduction of carbamazepine epoxidation.

L Bertilsson, T Tomson, G Tybring.   

Abstract

Drugs labeled with stable isotopes have been useful to study time-dependent changes in kinetics. Early studies suggested that carbamazepine (CBZ) may induce its own metabolism, but this could not be proved until tetradeuterium-labeled CBZ (CBZ-D4) was synthesized and then given to patients. CBZ-D4 was administered to three children during long-term treatment of epilepsy with CBZ. After 17 to 32 days of treatment, the plasma clearance of CBZ-D4 was doubled, but during the next four months, there was no further increase, indicating that autoinduction was complete within one month. Two patients with chronic alcoholism were treated with CBZ for five days. Half of the first dose of 600 mg was comprised of CBZ-D4. The half-life of this CBZ-D4 dose in the two patients (20 and 26 hr, respectively) was similar to the post-steady-state half-life of CBZ (23 hr in both patients) measured later. A single dose of CBZ given one week after the last maintenance dose had a longer half-life (46 and 45 hr, respectively), which probably is close to the disposition of the drug before starting the treatment with CBZ. This shows that autoinduction of CBZ metabolism was completed during the very first doses of CBZ. Autoinduction also disappeared rapidly after stopping the treatment. We have shown that it is mainly the epoxide-diol pathway that is induced, both during autoinduction and after induction with other antiepileptic agents.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3734137     DOI: 10.1002/j.1552-4604.1986.tb03558.x

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  15 in total

Review 1.  Stable isotopes in clinical pharmacokinetic investigations. Advantages and disadvantages.

Authors:  T R Browne
Journal:  Clin Pharmacokinet       Date:  1990-06       Impact factor: 6.447

Review 2.  Pharmacokinetics and Pharmacogenetics of Carbamazepine in Children.

Authors:  Natasa Djordjevic; Slobodan M Jankovic; Jasmina R Milovanovic
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2017-10       Impact factor: 2.441

Review 3.  Treating epilepsy in the elderly: safety considerations.

Authors:  S Arroyo; G Kramer
Journal:  Drug Saf       Date:  2001       Impact factor: 5.606

4.  Apparent autoinduction of valproate beta-oxidation in humans.

Authors:  D B McLaughlin; J A Andrews; W D Hooper; G R Cannell; M J Eadie; R G Dickinson
Journal:  Br J Clin Pharmacol       Date:  2000-05       Impact factor: 4.335

5.  Early stage autoinduction of carbamazepine metabolism in humans.

Authors:  I Bernus; R G Dickinson; W D Hooper; M J Eadie
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953

6.  In vivo binding characteristics of carbamazepine and carbamazepine-10,11-epoxide to serum proteins in paediatric patients with epilepsy.

Authors:  Y Kodama; K Tsutsumi; M Kuranari; H Kodama; I Fujii; M Takeyama
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

Review 7.  Clinical pharmacokinetics and pharmacological effects of carbamazepine and carbamazepine-10,11-epoxide. An update.

Authors:  L Bertilsson; T Tomson
Journal:  Clin Pharmacokinet       Date:  1986 May-Jun       Impact factor: 6.447

8.  Autoinduction and steady-state pharmacokinetics of carbamazepine and its major metabolites.

Authors:  T B Kudriakova; L A Sirota; G I Rozova; V A Gorkov
Journal:  Br J Clin Pharmacol       Date:  1992-06       Impact factor: 4.335

Review 9.  Optimisation of antiepileptic drug therapy. The importance of serum drug concentration monitoring.

Authors:  E Yukawa
Journal:  Clin Pharmacokinet       Date:  1996-08       Impact factor: 6.447

10.  Effect of sodium valproate on carbamazepine disposition and psychomotor profile in man.

Authors:  G J Macphee; J R Mitchell; L Wiseman; A R McLellan; B K Park; G T McInnes; M J Brodie
Journal:  Br J Clin Pharmacol       Date:  1988-01       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.